Johns Hopkins University NCTN Lead Academic Site Program

约翰霍普金斯大学 NCTN 牵头学术网站项目

• 批准号: 10579264
• 负责人: DEBORAH K ARMSTRONG
• 金额: $ 59.82万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-06 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10579264
• 关键词: Address; American College of Radiology Imaging Network; Cancer Center; Cellular biology; Clinical; Clinical Trials; Collaborations; Contracts; Development; Discipline; Disease; Early Diagnosis; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Faculty; Family; Goals; Grant; Image; Infrastructure; Institution; Laboratories; Lead; Leadership; Location; Malignant Neoplasms; Minority Participation; Mission; Modality; Molecular Biology; National Clinical Trials Network; Oncology; Patient-Centered Care; Patients; Phase; Prevention; Public Health; Quality of life; Radiation; Research; Research Personnel; Risk; Role; Site; Social Interaction; Techniques; Translational Research; Universities; cancer care; cancer therapy; early phase clinical trial; early phase trial; innovation; member; novel; novel marker; novel therapeutics; patient population; pre-clinical; programs; screening

Project Summary Johns Hopkins has been an academic member institution of cooperative groups since the founding of this national oncology research in 1955. Over the decades, our faculty have provided strong clinical and laboratory scientific leadership, and administrative leadership to the cooperative groups. Our primary goal is to provide scientific leadership thus bringing innovative translational science developed in pre-clinical and early phase trials at Johns Hopkins via mechanisms such as the ETCTN to the National Clinical Trials Network (NCTN) for further development. Our faculty serve in leadership roles as study PIs and laboratory PIs, disease and modality committee chairs. The majority of our contributions and our longest association remains with ECOG-ACRIN and secondly with NRG. The specific aims for our grant are 1) To provide scientific leadership within the NCTN groups and their disease-oriented committees. 2) To bring correlative translational research, novel imaging and radiation techniques, cell biology and molecular biology, into clinical trials for all stages of cancer. 3) To strengthen and enhance the coordinated, collaborative, and inclusive infrastructure established under one administrative program in order to support NCTN projects and promote participation in order NCI-supported projects, such as the ETCTN. 4) To address the challenges of supporting participation and accrual across disciplines, modalities, rare and diverse patient populations at all Johns Hopkins Kimmel Cancer Center locations. 5) To promote the involvement of junior faculty in all our aims for their advancement and contribution to the NCI cancer program. These goals will be accomplished through the mission of the Johns Hopkins Kimmel Cancer Center. The Center has achieved excellence in translational research through program project, RO1, and SPORE grants. In addition, early clinical trials of new drugs are conducted under the NCI phase I contract (since 1982). Also the ETCTN grant allows the development of early phase trials that incorporate novel biomarkers of activity in order to advance new treatments in the field. Johns Hopkins investigators have focused on enhancing minority participation in clinical trials through grants as well as increasing overall clinical trial accrual throughout Johns Hopkins Kimmel Cancer Center sites.

项目摘要 年以来，约翰霍普金斯一直是合作团体的学术成员机构。 1955年国家肿瘤学研究中心的成立几十年来，我们的教师 提供了强有力的临床和实验室科学领导，以及行政领导， 合作团体。我们的主要目标是提供科学的领导，从而带来创新 在约翰霍普金斯的临床前和早期试验中发展的转化科学， 国家临床试验网络（NCTN）等机制，以进一步 发展我们的教师担任研究PI和实验室PI，疾病 和模式委员会主席。我们的大部分贡献和我们最长的联系 仍然是ECOG-ACRIN，其次是NRG。我们拨款的具体目的是：1） 在NCTN小组及其疾病导向委员会中提供科学领导。（二） 将相关的转化研究、新型成像和放射技术、细胞生物学 和分子生物学，用于癌症各个阶段的临床试验。3)加强和增进 在一个行政机构下建立的协调、协作和包容的基础设施 计划，以支持NCTN项目，并促进参与，以使NCI支持 项目，如ETCTN。4)应对支持参与和 所有约翰霍普金斯医院的学科、模式、罕见和多样化患者人群的累积 Kimmel癌症中心的位置。5)促进初级教师参与我们的所有目标 表彰他们对NCI癌症项目的进步和贡献。这些目标将是 通过约翰霍普金斯金梅尔癌症中心的使命来完成。中心 通过项目、RO 1和SPORE，在转化研究方面取得了卓越的成就。 赠款。此外，新药的早期临床试验在NCI I期下进行 合同（自1982年起）。此外，ETCTN赠款允许开发早期试验， 结合新的活性生物标志物，以推进该领域的新治疗。约翰 霍普金斯的研究人员一直致力于通过以下方式提高少数群体对临床试验的参与度： 赠款以及增加整个约翰霍普金斯金梅尔的整体临床试验应计费用 癌症中心网站。